In the COMBAT trial, treatment of pancreatic tumors with a C-X-C motif chemokine receptor 4 (CXCR4) antagonist decreased infiltration of MDSCs and was synergistic with immune checkpoint blockade in pancreatic cancer [51]. The gene discussed is CXCR4; the disease is familial pancreatic carcinoma.